Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright‘s price objective indicates a potential upside of 307.17% from the stock’s current price.
RNAC has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cartesian Therapeutics in a research note on Wednesday, September 9th. Wall Street Zen upgraded shares of Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday, August 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Cartesian Therapeutics in a report on Tuesday, September 29th. Finally, Zacks Research raised shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.60.
View Our Latest Stock Analysis on RNAC
Cartesian Therapeutics Price Performance
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.63. Sell-side analysts expect that Cartesian Therapeutics will post -2.19 earnings per share for the current year.
Hedge Funds Weigh In On Cartesian Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC raised its stake in Cartesian Therapeutics by 0.7% during the 2nd quarter. Squarepoint Ops LLC now owns 2,254,619 shares of the company’s stock valued at $23,493,000 after acquiring an additional 16,133 shares in the last quarter. Marshall Wace LLP boosted its position in Cartesian Therapeutics by 4.6% during the 3rd quarter. Marshall Wace LLP now owns 243,545 shares of the company’s stock worth $1,756,000 after acquiring an additional 10,626 shares during the period. Privium Fund Management B.V. boosted its position in Cartesian Therapeutics by 2.2% during the 3rd quarter. Privium Fund Management B.V. now owns 155,000 shares of the company’s stock worth $1,118,000 after acquiring an additional 3,325 shares during the period. Renaissance Technologies LLC boosted its position in Cartesian Therapeutics by 63.7% during the 1st quarter. Renaissance Technologies LLC now owns 67,300 shares of the company’s stock worth $414,000 after acquiring an additional 26,200 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Cartesian Therapeutics in the second quarter worth $332,000. 86.95% of the stock is owned by institutional investors.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics is a clinical-stage biotechnology company developing RNA-engineered cell therapies for autoimmune diseases and cancer. Its platform uses messenger RNA to program immune cells, including T cells, to recognize and target disease-associated cells. The company’s lead program, Descartes-08, is an autologous CAR T-cell therapy designed to target BCMA and being studied for generalized myasthenia gravis. Unlike gene-modified cell therapies that rely on permanent genetic changes, Cartesian’s approach uses RNA to produce temporary cell modifications.
Further Reading
- Five stocks we like better than Cartesian Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
